Tree Nut Allergy Market

U.S. Tree Nut Allergy Market Outlook 2031

• The tree nut allergy market in the U.S. was valued at US$ 233.7 Mn in 2021
• The market in the country is projected to grow at a CAGR of 6.5% from 2022 to 2031
• The tree nut allergy market in the U.S. is anticipated to reach US$ 433.2 Mn by the end of 2031

Analysts’ Viewpoint on Tree Nut Allergy Market Scenario

Tree nut allergy is a common food allergy found in children as well as adults. It can cause major health issues due to allergic granulation of proteins found in tree nuts. Incidence of tree nut allergy varies with geographical location and dietary habits. Companies operating in the U.S. tree nut allergy market should focus on diagnosis and treatment of food allergies with antihistamines. Rise in prevalence of peanut and walnut allergies, surge in consumption of tree nuts in the U.S. for their nutritional value, and changes in lifestyle & environment are expected to propel the market in the U.S. in the next few years.

Overview of U.S. Tree Nut Allergy Market

Food allergy is a condition, wherein certain foods trigger an abnormal immune response. It occurs when the immune system incorrectly classifies specific proteins in food as harmful. Food allergy has become more common across the world, with complete avoidance being the only proven treatment. The term “allergy to tree nuts” includes allergies to almonds, Brazil nuts, cashew nuts, hazelnuts, chestnuts, macadamia nuts, pecan nuts, pistachios, and walnuts. All tree nuts belong to five orders of plants: beech (Fagales), soapwood (Sapindales), silverberry (Proteales), heather (Ericales), and rosewood (Rosales). Tree nut allergies affect the majority of the people; the patient’s body responds by launching a series of defense mechanisms, including the release of inflammatory substances such as histamines. Tree nuts can induce anaphylaxis. Therefore, patients are advised to limit their exposure to them by reading product labels and inquiring about ingredients before ingesting new foods and beverages. They should also learn how to use epinephrine if they develop swelling of lips and difficulties in breathing after being exposed to the allergen.

Tree nut allergies typically begin in childhood, but unlike other food allergies, they seldom go away and frequently last a lifetime. Tree nut allergies are one of the leading causes of life-threatening allergic responses in children and adults. Allergies to tree nuts and peanuts have been rising in the U.S. According to an independent research study, the number of children in the U.S. with food allergies has increased by about 4% every year since 1997. The number of emergency room visits for food-induced anaphylaxis in the U.S. has more than tripled over the last decade.

Request a sample to get extensive insights into the Tree Nut Allergy Market

Publicity Efforts to Promote Nutritional Advantages of Tree Nuts in U.S. to Drive Market

Consumption of tree nuts in the U.S. increased by 45% between the mid-1990s and the mid-2000s, with almond being the most popular tree nut. Increase in per capita tree nut consumption can be ascribed to the rise in publicity efforts regarding nutritional advantages of nuts, such as their high quantities of vitamin E and omega fatty acids. Increase in popularity of Mediterranean and Middle Eastern foods that contain nuts; and the movement toward better eating are driving the demand for tree nuts.

Strong domestic and global demand for tree nuts farmed in the U.S. has kept prices high despite the rise in production. The number of pistachio farms is increasing at a faster rate than any of the crops. The U.S. currently generates 48% of the global pistachio supply. Per capita pistachio consumption has more than tripled over the last decade, with the U.S. producing its first billion-pound harvest in 2020. Hence, demand for tree nut allergy treatment is increasing in the U.S, thus creating immense opportunities for players in the tree nut allergy market in the country.

High Prevalence of Walnut Allergies to Propel U.S Tree Nut Allergy Market

Tree nut allergies, such as those to walnuts, are prevalent and often severe in the U.S. These allergies usually appear around the age of two. The number of tree nuts to which a person is allergic could rise as he/she gets older. The walnut segment dominated the tree nut allergy market in the U.S. with around 33.3% share in 2021. The Food Allergy and Anaphylaxis Network (FAAN) analyzed data of 5,149 people in the U.S. and reported that among all the tree nut allergies, walnuts and cashew nuts accounted for the majority share of around 50%. This is expected to drive the market in the U.S. during the forecast period.

Request a custom report on Tree Nut Allergy Market

Increase in Availability and Effectiveness of Antihistamines and Epinephrine to Drive Market

The antihistamines treatment segment dominated the tree nut allergy market in the U.S., accounting for around 53.7% share in 2021. Tree nut allergy has no known treatment available. Antihistamines are commonly used to treat patients with a single mild symptom (e.g., itching, sneezing, or rashes). Walnut allergy treatment with the help of antihistamines is creating opportunities for market players. Epinephrine is also the first line of treatment for food allergy-related anaphylaxis. It is usually delivered through an auto-injector. Epinephrine reverses anaphylaxis by binding to receptors of the lungs and causing the muscles around the airways to relax. Epinephrine can also prevent the release of more histamines, stopping the progression of the reaction. Increase in R&D in peanut allergy treatment and cashew nut allergy treatment is expected to drive the market during the forecast period.

Growth in Number of Retail Pharmacies in U.S. Creating Significant Opportunities for Market Players

The retail pharmacies distribution channel segment accounted for 45.7% share of the market in the U.S. in 2021. This can be ascribed to the presence of large number of retail pharmacies across the country and convenient & easy availability of antihistamines in the market. Growth of retail pharmacies can be primarily ascribed to the easy availability of drugs and rise in collaboration of health care practitioners. People are more likely to opt for retail pharmacies to buy medicines due to the discounts offered by these pharmacies. Stakeholders operating in the U.S. tree nut allergy market are experiencing lucrative growth opportunities due to the rise in demand for antihistamines in retail pharmacies.

Analysis of Key Players in U.S. Tree Nut Allergy Market

The tree nut allergy market in the U.S. is consolidated, with a small number of key players accounting for majority of the share. Most companies are investing significantly in research & development activities. Expansion of product portfolios and mergers & acquisitions are key strategies adopted by market players. Prominent players operating in the market include Bayer AG, Teva Pharmaceuticals USA, Inc., Pfizer, Inc., Amphastar Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., and Kaleo, Inc.

Key Developments in U.S. Tree Nut Allergy Market

• In November 2021, in order to address the shortage of EpiPen, Pfizer started coordinating with the FDA to extend the expiration dates of specific lots of EpiPen 0.3 mg auto-injectors and its authorized generic version after carefully reviewing the product stability data
• In January 2021, Ukko, a biotech company with the mission to eliminate food allergies and sensitivities, announced US$ 40 Mn in new Series B funding. Ukko harnesses artificial intelligence (AI) and protein engineering to develop healthier food and therapies for food allergies. The new funding is expected to enable Ukko to enter clinical trials with its investigational therapeutic for peanut allergies. It would also accelerate the development of Ukko’s gluten, which is designed for people with celiac and other gluten sensitivities. The round was led by Leaps by Bayer – the impact investment arm of Bayer.
• In April 2020, Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (“FDA”) had approved its Abbreviated New Drug Application (“ANDA”) for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial. Amphastar’s newly approved drug product was determined by the FDA to be therapeutically equivalent to Adrenalin (Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial) distributed in the U.S. by Par Pharmaceutical, Inc.

Each of these players has been profiled in the tree nut allergy market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments. In the report, the tree nut allergy treatment market outlook is provided by focusing on the demand analysis of U.S. tree nut allergy treatment options.

U.S. Tree Nut Allergy Market Snapshot